Regular exercise is good for your heart, no matter how old you are!

Regular exercise is highly beneficial for all patients with cardiovascular disease regardless of age, report investigators. Their results showed that the patients who benefited most from cardiac rehabilitation were those who started out with the greatest physical impairment.

Read more

Large genome-wide association study illuminates genetic risk factors for gout

Researchers, using a method called genome-wide association study, have illuminated the genetic underpinnings of high serum urate, the blood condition that brings on gout. The study will inform efforts to develop screening tests for gout risk as well as potential new treatments.

Read more

Treating pulmonary embolism: How safe and effective are new devices?

A new scientific statement identifies the risks and benefits of novel interventional devices compared to anticoagulation alone in the treatment of patients with pulmonary embolism. Authors conclude there is little data — particularly, as it pertains to the treatment of patients with 'intermediate-risk PE' — that suggests these interventional approaches are more safe and effective than the use of anticoagulation alone.

Read more

Scientists ID new targets to treat fibrosis, a feature of many chronic diseases

When it comes to repairing injured tissue, specialized cells in the body known as fibroblasts are called into action. Fibroblasts give rise to healing cells called myofibroblasts, which generally is good in the short term — but bad when myofibroblast activation gets out of hand. Now, researchers show how fibroblast activation and myofibroblast formation occurs, providing clues for how to target fibrosis — which impacts several chronic diseases.

Read more

Ibrutinib linked to high blood pressure and other heart problems, study suggests

Over half of people prescribed the targeted blood cancer-fighting drug ibrutinib developed new or worsened high blood pressure within six months of starting the medication. The analysis is also the first to tie ibrutinib-related hypertension to a heightened risk of heart problems, particularly atrial fibrillation. Moreover, the association of ibrutinib with cardiovascular complications remained regardless of the prescribed dose.

Read more